Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
  1. No Image 01Jun
    by

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  2. No Image 01Jun
    by

    More than half of Korean biopharma firms view R&D investments as assets.

  3. No Image 03Mar
    by

    Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

  4. No Image 01Jun
    by

    Oscotec shares rebound on launch of US clinical trial

  5. No Image 01Jun
    by

    Oscotec wins exception policy for continued R&D for new drugs

  6. No Image 01Jun
    by

    Oscotec`s acute leukemia treatment wins orphan drug status from FDA

  7. No Image 01Jun
    by

    Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

  8. No Image 15Sep
    by

    Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

  9. No Image 27Feb
    by

    Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

  10. No Image 03Mar
    by

    Other news to note for March 2, 2021

  11. No Image 01Jun
    by

    Profiles of Four New Stock-Billionaires

  12. No Image 01Jun
    by

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.